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Abstract
Ketamine is a well-known anesthetic agent and a drug of abuse. Despite its widespread use and abuse, little is known about
its long-term effects on the central nervous system. The present study was designed to evaluate the effect of long-term (1-
and 3-month) ketamine administration on learning and memory and associated gene expression levels in the brain. The
Morris water maze was used to assess spatial memory and gene expression changes were assayed using Affymetrix
Genechips; a focus on the expression of GABAA receptors that mediate a tonic inhibition in the brain, was confirmed by
quantitative real-time PCR and western blot. Compared with saline controls, there was a decline in learning and memory
performance in the ketamine-treated mice. Genechip results showed that 110 genes were up-regulated and 136 genes were
down-regulated. An ontology analysis revealed the most significant effects of ketamine were on GABAA receptors. In
particular, there was a significant up-regulation of both mRNA and protein levels of the alpha 5 subunit (Gabra5) of the
GABAA receptors in the prefrontal cortex. In conclusion, chronic exposure to ketamine impairs working memory in mice,
which may be explained at least partly by up-regulation of Gabra5 subunits in the prefrontal cortex.
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Introduction
Ketamine, a derivative of phencyclidine hydrochloride (PCP), is
a common anesthetic for medical and veterinary purposes. Like
PCP, ketamine induces dissociative anesthesia at clinical doses [1].
Ketamine is also used as a recreational drug at nightclubs, dance
parties, and rave scenes where it is commonly known as ‘‘Special
K’’, ‘‘Vitamin K’’ or ‘‘SuperK’’ [2]. Although ketamine is a
controlled drug, its illicit use has increased rapidly in many
countries and areas including the United States [3], Australia [4]
and China [5].
The growing abuse of ketamine has raised concerns about its
possible toxic effects. Pharmacologically, acute effects of ketamine
include hypertension, tachycardia and visual alterations [6]. N-
methyl-D-aspartate (NMDA) receptors are known to be intimately
involved in regulating synaptic plasticity and memory function [7].
Ketamine is a non-competitive NMDA receptor antagonist, and
not surprisingly causes impairments of working memory and
cognitive function following acute dosing [8]–[9]. The acute effects
of ketamine on memory are known, but little information is
available to indicate the cognitive consequences following its long-
term use [10]. Of particular concern, therefore, are results from a
recent study showing hyperphosphorylation of tau in the brains of
rodents and monkeys after prolonged administration [11]. Long-
term ketamine administration also was shown to have detrimental
proapoptotic effects on neurons, via an elevation of the Bax/Bcl-2
ratio and activation of caspase-3 [12]. Whilst the former studies
indicate structural changes in the brain after chronic exposure to
ketamine, it is not known if it translates to long lasting effects on
cognition.
Besides blocking NMDA receptors, ketamine also binds with
reasonable affinity m-opioid receptors and sigma receptors [13],
[14]. Further, anesthetic effects of ketamine probably also involve
an activation of GABAA receptors, which provide a major
inhibitory control of neurotransmission in the central nervous
system [15]. Consistent with the pharmacology of ketamine, a
recent microarray study showed gene expression changes after
repeated administration of ketamine in the brains of postnatal rats
in various pathways linked with neurotransmission receptor
signaling, such as glutamate, dopamine and GABAA receptor
[16]. However, gene expression changes have yet to be determined
in the CNS following long-term ketamine abuse.
The prefrontal cortex (PFC), the anterior part of the frontal
lobes, is regarded to be heavily involved in the central executive
control of cognitive processing [17]. Alterations of interconnec-
tions among neurons in the PFC have been hypothesized to lead to
a failure to integrate information with a subsequent decline of
cognitive function [18]. In addition, the PFC is considered to be
vulnerable to drug of abuse [19]. In the present study, we first
investigated cognitive performance of mice in a long-term sub-
anesthetic ketamine abuse model [11], and then checked gene
expression changes in the PFC. Our results showed that increased
Gabra5 was inversely related with learning and memory in long-
term ketamine treated mice.
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Animals and drug administrations
All animal experiments were approved by the Animal
Experimentation Ethics Committee (AEEC) of the Chinese
University of Hong Kong (CUHK) and were performed under
license of the Department of Health, the Government of the
Hong Kong SAR, according to the Animals (Control of
Experiments) Ordinance Chapter 340(Animal License ID: (10–
297) in DH/HA&P/8/2/1 Pt.13). One-month old male ICR
mice were obtained from the Laboratory Animal Services Centre
(CUHK), and housed at 22u–24uC with 45%–55% humidity and
a 12-hour alternating light-dark cycle. Standard diet (PicoLab
Rodent Diet 20, PMI Nutrition Inc., Henderson, USA) and water
were available ad libitum. The anesthetic dose of ketamine in mice
is 100 mg/kg [20], and in our previous used 30 mg/kg
[11].Therefore, in the present studies, ketamine (Alfasan Inc.,
Utrecht, Holland) was administered intraperitoneally once per
day at the sub-anesthetic dose of 30 mg/kg while the same
volume of normal saline (0.9% w/v) was used as control. Body
weights of the mice were measured weekly and doses adjustment
appropriately. After 1 and 3 months, the mice were tested in
behavioral studies and then sacrificed for subsequent gene
expression analysis.
Morris water maze
Learning and memory was assessed using a spatial acquisition
task in a Morris water maze as previously described [21]. The
apparatus was an open circular pool with a diameter 1.2 m filled
to a depth of 0.5 M with tap water (2361uC), which was made
opaque by the addition of non-toxic black ink. The pool was
divided into four equal quadrants and 4 cue cards were erected
around the pool in each quadrant. A circular 12 cm diameter
platform of was placed approximately 1 cm under the water
surface to make it invisible to the mice. The position of the
platform and the cue cards remained the same throughout the
whole experiment. Mice (n=12 from each group) were trained
for 4 consecutive days, with 4 trials on each day. During each
trial, individual mice were put in a randomly chosen quadrant in
the pool with the head toward the pool wall. Each mouse was
given 60 seconds(s) to search for and locate the submerged
platform. If a mouse failed to locate the platform within 60 s, it
would be guided gently to the platform. After arriving at the
platform, the mouse was allowed to stay on it for 30 s. The
latency time to find the platform was recorded and the average
time from 4 trials represented as the daily result for the mouse.
To eliminate the influence of the anesthetic effects of ketamine
during behavioral studies, the tests were performed 4 hours after
the last injection.
Brain tissue collection and RNA extraction
At the end of 1 or 3 months and following behavioural testing,
the mice were killed and the brains were carefully removed and
washed in cold saline. The prefrontal cortex was located by
reference to a mouse brain atlas [22] and dissected out
immediately. For microarray and real-time PCR analysis, the
tissues were soaked in RNAlater (Qiagen Inc., Valencia, CA,
USA) and stored at 4uC for no more than 2 weeks. Total RNA
was isolated from brain tissues using RNeasy Lipid Tissue Mini
Kits (Qiagen Inc., Valencia, CA, USA) according to the
manufacture’s protocol. The yield of total RNA was measured
at 260 nm using a Spectrophotometer. For western blot, brain
tissues were rapidly frozen in liquid nitrogen and stored at 280uC
until use.
Microarray analysis
Two samples from the 3 month ketamine group and 2 from the
3 month saline group were randomly chosen for use in the
Microarray analysis (n=4). Purity and integrity of RNA samples
were evaluated using a RNA 6000 LabChip kit in an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto,CA, USA). The
samples had a high quality and integrity with A260/A280 between
1.9 and 2.1 and RIN (RNA integrity number) greater than
8.5(data not show). We used the Mouse Gene 1.0 ST GeneChip
(Affymetrix Inc., Santa Clara, CA, USA) (n=4). This array
interrogates 28,853 well annotated genes offering whole-transcript
coverage. The genechip process, specifically sample labeling,
hybridization, stringent washing, staining and scanning of arrays,
was performed at the Genome Research Centre, the University of
Hong Kong. Quality control assessment of the gene expression
data were performed using Affymetrix Expression Console
TM
software. After passing quality control, data were further analyzed
for fold changes and Gene Ontology (GO) analysis using
GeneSpring GX 9 software (Agilent Technologies, Palo Alto,
CA, USA).
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) (n=6 per group) was
performed as previously described [23], with minor modifications.
Briefly, cDNA was synthesized in a 20 ml reaction volume
containing 1 ml oligo(dT)12–18 (500 mg/ml), 5 mg total RNA, 1 ml
dNTP mix(10 mM each) and 200 units Moloney murine
leukaemia virus (M-MLV) Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). The amplification reactions were performed
using a 7900 HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) in 96 well plates. The PCR
cycle parameters were 10 min at 95uC, and 40 cycles at 95uC for
15 s and 60uC for 60 s. Total 50 ml reaction volumes included
25 ml Power SYBRH Green PCR Master Mix kit (Applied
Biosystems, Foster City, CA, USA), 1 ml cDNA and 1 ml forward
and reverse primers (500 mmol/l). The primers of GABAA
receptor alpha 1–5 subunits and endogenous b-Actin were
designed using Primer Premier 5.0 (Premier Biosoft International,
Palo Alto, California, USA). The primer sequences and PCR
product lengths are shown in Table 1.We chose crossed-intron
primers to eliminate possible genomic DNA contaminants in the
amplification process. The specificity of amplification was also
confirmed by melting curve analysis with one single peak at qRT-
PCR reactions. Each sample was analyzed in triplicate and
normalized to endogenous control. The fold-changes of gene
expression between the ketamine and saline groups were
calculated using 2
-Delta Delta Ct methodology [24].
Western blot
For western blots [25] , frozen brain tissues (n=6 from each
group) were thawed and homogenized in 300 ml RIPA lysis buffer
supplemented with protease inhibitor cocktail (Millipore Inc.,
Billerica, MA, USA). The lysates were centrifuged at 14,000 g at
4uC for 30 min and the supernatants were collected and stored at
220uC until use. Protein concentration was determined by the
Bio-Rad DC protein assay (Bio-Rad Laboratories Inc., Hercules,
CA, USA). Each sample of 50 mg protein was separated by 10%
SDS-PAGE electrophoresis using 100 Volt for 2 hours and then
transferred to a PVDF membrane at 200 mA for 60 min. The
membrane was blocked with 5% non-fat dry milk for 1 h at room
temperature and then incubated overnight at 4uC with primary
antibodies diluted as followed: GABRA1 (1:1,000) (ab94585,
Abcam, Cambridge, MA, USA), GABRA5 (1:1,000) (AB9678,
Millipore, Billerica, MA, USA), b-actin (1:20,000) (MAB1501,
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times with 0.05% Tween-20 and phosphate buffered saline, the
membrane was incubated with the corresponding horseradish
peroxidase (HRP) conjugated secondary antibody for 1 h at room
temperature. Blots were then developed using an ECL Plus Kit
(Millipore) on Fuji Medical X-ray film and scanned using a Bio-
Rad 6500 scanner. Optical density was quantified with Quantity
One software (Bio-Rad).
Statistical analysis
Significance of differences between Morris water maze datawere
assessed by repeated measures ANOVA. Results of qRT-PCR and
western blot were compared by independent-sample t-test.
Calculations were done using SPSS software (version 15.0).
Differences were considered significant when p,0.05.Data are
presented as mean 6SD.
Results
Behavioral studies
The Morris water maze was used to assess spatial memory. The
times of the mice to find the escape platform were recorded. On
day 1, there were no statistical differences between the latency
times of the animals in the ketamine or control group to reach the
hidden platform. However, on day 4, the ketamine treated animals
needed a significantly longer time compared with the saline
treated animals to find the platform (p,0.05). Repeated measures
ANOVA revealed consistent significant effect of long-term
ketamine administration on latency times (Figure 1), suggesting
that there was a decline of cognitive ability compared with saline
controls (p,0.05).
Microarray analysis
The microarray results of this study were deposited in the NCBI
Gene Expression Omnibus database (Accession Numbers:
GSM647254- GSM647257). Data revealed that 110 genes were
up-regulated and 136 genes were down-regulated more than 1.3
folds in the brains of the ketamine-treated mice (Table 2). These
246 genes were further explored using GO analysis. The gamma-
aminobutyric acid signaling pathway (GO: 0007214) and the
index of GABAA receptor activity (GO: 0004890) were amongst
the 12 most significantly affected systems (Table 3). The change for
Gabra5 (Accession number: NM_000810) was +1.65 fold.
Quantitative real-time PCR
To confirm the genechip results, mRNA levels of 5 GABAA
receptor subunits, namely Gabra1-5, were evaluated by qRT-
PCR. After 1month ketamine administration, Gabra5 mRNA
levels in the prefrontal cortex of the ketamine treated mice was
2.3660.85 fold higher than levels observed in the control saline
group (p,0.05). Similarly, significant changes of Gabra5 were also
found in the animals treated for 3 months (1.496360.08264 fold,
p,0.05) (Figure 2). Conversely, there was no significant difference
in gene expression levels for other GABAA receptor subunits
following for 1 and 3 months ketamine treatment, respectively
(p.0.05) .
Western blot
Western blots were performed to investigate the protein level
changes of GABAA receptors in ketamine treated mice. Fold
changes and representative images of western blot results are
shown in Figure 3. Figure 3(A) shows western blot results of
Gabra5. Gabra5 was significantly up-regulated following 1 and 3
months treatment with ketamine when compared with the
respective controls (1.9760.55 for 1 month, 2.5660.81 for 3
months, p,0.05; Figure 3(A)). For Gabra1, no significant changes
were found at 1 month (0.7460.31 p.0.05), but at 3 months, a
marginal significant difference was observed (1.2460.17, p=0.05,
Figure 3(B)).
Discussion
The major finding of the present study was that long-term
ketamine administration impaired working memory and up-
regulated the Gabra5 gene in the prefrontal cortex (PFC).These
results suggest that long-term ketamine administration use may
affect cognition by increasing the activity of a tonic GABA
signaling system.
NMDA receptors are the major excitatory ligand-gated ion
channel in CNS [26], [27]. Moreover, activation of NMDA
receptors plays a vital role in mechanisms of long-term
potentiation (LTP), which is believed to be a fundamental key
facilitating synaptic plasticity and memory formation [7]. Thus,
blocking NMDA receptors predictably disrupts LTP and impairs
cognition [28], [29]. Indeed, the short-term use of ketamine has
been found to impair memory in human subjects [9]. In another
study, the short-term use of ketamine impacts on memory process
during recruitment of frontal–parietal regions as revealed by
neuroimaging [30]. In our studies, long-term injection of ketamine
impaired learning and memory during its ongoing scheduled
administration. Following one-month of treatment, mice on the
control saline schedule found the hidden platform quickly after 3
days of training, while mice that had received ketamine spent
more time to locate it. After 3 months, the latency times of mice on
the ketamine schedule hardly declined (see Figure 1). It is worthy
Table 1. Primers for quantitative real-time PCR analysis.
Gene Primer sequence(59–39) Product length(bp)
Forward Reverse
Gabra1 CCA AGT CTC CTT CTG GCT CAA CA GGG AGG GAA TTT CTG GCA CTG AT 111
Gabra2 TTA CAG TCC AAG CCG AAT GTC CC ACT TCT GAG GTT GTG TAA GCG TAG C 103
Gabra3 CAA GAA CCT GGG GAC TTT GTG AA AGC CGA TCC AAG ATT CTA GTG AA 119
Gabra4 GAG ACT GGT GGA TTT TCC TAT GG GGT CCA GGT GTA GAT CAT CTC ACT 94
Gabra5 CCC TCC TTG TCT TCT GTA TTT CC TGA TGT TGT CAT TGG TCT CGT CT 99
b-Actin AGG CCA ACC GTG AAA AGA TG ACC AGA GGC ATA CAG GGA CAA 101
doi:10.1371/journal.pone.0021328.t001
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ments between the 1- and 3-month control animals on the saline
schedule; indeed data from the 3-month animals were close to the
animals that had received ketamine for 1-month. However, a more
detailed analysis revealed that the trend of latency times for the 3
month saline treated animals mice improved daily, while there was
no significant improvement at day 4 as compared with day 3 in the
animals on the 1-month ketamine schedule. The age-related
effects that we observed in the saline treated animals was
predictable, since previous studies have shown that young mice
aged 60 days show significantly better performance than older
mice in maze learning tasks [31].
The effects of ketamine can be attributed to its ability to act as a
reversible NMDA receptor antagonist and following metabolism
(half life 2.5 h) the effects are transient [32]. However, the effect
following long-term abuse may be more profound. In the present
study, we found gene expression changes in GABAA receptors as
shown in the microarray results, which were also confirmed by the
quantitative real-time PCR. This is consistent with evidence
showing enhanced GABAA receptor-mediated inhibition following
ketamine injection. Thus, in guinea-pig olfactory cortical slices,
ketamine has been shown to prolonging inhibition through
potentiating the GABAA receptor-mediated inhibitory postsynap-
tic currents [33]. In Xenopus oocytes expressing mouse cortical
GABAA receptors, ketamine enhanced inhibitory Cl
2 currents
[34]. Some indirect evidence for ketamine acting as a GABAA
receptor agonist is also seen in vivo where ketamine-induced
anesthesia is partly mediated by an enhancement of central
inhibitory GABA transmission [15]. As shown in our animal
studies, mRNA levels of Gabra5 increased significantly after 1-
and 3-month of ketamine administration. In the 3-month group,
although the fold changes had decreased, significant changes were
still found. Similarly, gene expression changes of Gabra5 were also
confirmed by the using western blot. Gabra5 protein levels were
found significantly higher in both of 1- and 3-month ketamine
groups than that of their controls. Although no significant changes
were found in Gabra1 levels, there were slight increases in fold
changes in the 3-month group for Gabra1 as compared with 1-
month group. Additionally, trends in fold changes of mRNA and
protein levels were different. There may be several reasons of this
discrepancy. Firstly, continuously up-regulation of mRNA would
cause excessive protein synthesis, which may lead to a cumulative
effect of protein levels in GABAA receptors and thus the fold
Figure 1. Spatial learning and memory performance of mice in the Morris water maze following 1 (1M) and 3 months (3M)
treatment with ketamine. Significant differences between groups were analyzed using a repeated Measures ANOVA. 1M saline vs 1M ketamine,
p,0.05; 3M saline vs 3M ketamine, p,0.05.
doi:10.1371/journal.pone.0021328.g001
Table 2. Numbers of different expressed genes in the brain
of ketamine treated mice.
Fold Change Total Gene no. No. up-regulated No. down-regulated
.2.0 12 2 10
.1.9 21 3 18
.1.8 27 5 22
.1.7 37 12 25
.1.6 45 18 27
.1.5 64 25 39
.1.4 103 41 62
.1.3 246 110 136
doi:10.1371/journal.pone.0021328.t002
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Secondly, many studies have also reported changes of GABAA
receptors in aging and degeneration [35], [36], [37]. An increased
in GABAA receptors density was thought to be the results of
compensatory effects following neuronal cell loss during aging
[38]. The levels of GABAA receptors may also be regulated by cell
signaling pathways. It was reported that serum levels of brain-
derived neurotrophic factor (BDNF) were increased in chronic
ketamine users [39]. Increased BDNF was also found in rat brains
following prolonged ketamine exposure [40]. Elevation of BDNF
probably induces a rapid increase the total number of cell surface
GABAA receptors through activation of Trk B receptor tyrosine
kinases [41]. It would be interesting in future studies to examine
whether the BDNF/TrkB/GABAA signaling pathway has
changed in ketamine treated mice.
GABAA receptors mediate fast-acting inhibitory response in the
brain and activation of GABAA receptors causes hyperpolarization
and decreased activity of neurons [42]. The GABAA receptor
system also plays a roles in memory and synaptic plasticity [43].
Compounds that enhance the action of GABA can impair
memory processing, while conversely, compounds that reducing
the action of GABA can enhance memory processing, especially
the acquisition process [44].There are a total of a GABAA receptor
subunits and they have also shown differential distribution in the
brain [45]. Gabra5 is predominantly expressed in brain areas
important for memory processing such as level VI of cortex, and
also in the hippocampus [46]. Gabra5 sets the threshold for LTP
and constrains certain forms of memory through mediation of
synaptic inhibition, with genetic deletion or pharmacological
inhibition of the activity of Gabra5 greatly reducing the threshold
Table 3. 12 most statistically significant changed terms in the Gene Ontology analysis.
GO ACCESSION GO Term p-value
GO:0042136 neurotransmitter biosynthetic process 0.000175264
GO:0007214 gamma-aminobutyric acid signaling pathway 0.000382054
GO:0042401 biogenic amine biosynthetic process 0.000563124
GO:0004890 GABA-A receptor activity 0.000666473
GO:0042398 amino acid derivative biosynthetic process 0.000721329
GO:0016917 GABA receptor activity 0.000837374
GO:0042133 neurotransmitter metabolic process 0.001027183
GO:0003677 DNA binding 0.001408004
GO:0008292 acetylcholine biosynthetic process 0.001535487
GO:0004753 saccharopine dehydrogenase activity 0.001535487
GO:0047131 saccharopine dehydrogenase (NAD+, L-glutamate-forming) activity 0.001535487
GO:0005307 choline:sodium symporter activity 0.001535487
doi:10.1371/journal.pone.0021328.t003
Figure 2. Gene expression changes of 5 GABAA receptor subunits in the prefrontal cortex as reveled by quantitative real-time PCR.
Significant gene expression changes were found for Gabra5 (* p,0.05).
doi:10.1371/journal.pone.0021328.g002
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Gabra5 in the prefrontal cortex at 1- and 3-months (*p,0.05, ** p,0.05). (B) Fold change of the protein Gabra1 in the prefrontal cortex at 1- and 3-
months. (C) Representative images of western blot results for Gabra5 and Gabra1.
doi:10.1371/journal.pone.0021328.g003
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showed treatment effects of aging associated memory decline in
APP/PS1 transgenic mice [50]. Our study found that increased
Gabra5 was inversely related to learning and memory following
long-term ketamine treatment in mice. In particular, the learning
and memory impairments were found in the 3-month ketamine
treatment group, which appears in line with a recent study in
human subjects [10]. Further physiological studies should focus on
whether there is increased inhibitory currents via GABAA receptor
mediated Cl
2 elicitation in long-term ketamine treated animals,
and if such changes are reversible. Such studies would be helpful in
further understanding the mechanisms of ketamine induced
memory impairment.
In conclusion, we have shown that prolonged use of ketamine at
a sub-anesthetic dose can impair cognitive function in mice. We
also found a significant up-regulation of Gabra5 subunit in the
prefrontal cortex of the ketamine treated animals. Thus, this study
has revealed, for the first time, that long-term of ketamine
administration and associated memory impairments may be
related to an up-regulation of Gabra5 subunits in the prefrontal
cortex.
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